$SLNO
SOLENO THERAPEUTICS INC

2018 Q2 Form 10-Q Financial Statement

#000119312518164124 Filed on May 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $265.0K
YoY Change -100.0% -100.0% -40.72%
Cost Of Revenue $209.0K
YoY Change -54.66%
Gross Profit $56.00K
YoY Change -500.0%
Gross Profit Margin 21.13%
Selling, General & Admin $1.770M $1.870M $1.046M
YoY Change -19.36% 78.78% -57.77%
% of Gross Profit 1867.86%
Research & Development $1.714M $1.180M $327.0K
YoY Change 121.73% 260.86% -81.55%
% of Gross Profit 583.93%
Depreciation & Amortization $490.0K $490.0K $150.0K
YoY Change 16.67% 226.67% 650.0%
% of Gross Profit 267.86%
Operating Expenses $3.413M $3.475M $1.373M
YoY Change 14.99% 153.1% -67.69%
Operating Profit -$3.413M -$3.475M -$1.373M
YoY Change 14.99% 153.1% -67.79%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$3.222M $185.0K -$672.0K
YoY Change 3561.36% -127.53% -162.57%
Pretax Income -$6.640M -$3.290M -$2.050M
YoY Change 116.99% 60.49% 4.06%
Income Tax
% Of Pretax Income
Net Earnings -$7.058M -$3.804M -$2.887M
YoY Change 77.83% 31.76% -9.47%
Net Earnings / Revenue -1089.43%
Basic Earnings Per Share
Diluted Earnings Per Share -$346.9K -$194.6K -$567.8K
COMMON SHARES
Basic Shares Outstanding 19.77M shares 19.49M shares 47.48M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.59M $14.87M $10.54M
YoY Change 66.75% 41.08% 62.4%
Cash & Equivalents $12.59M $14.87M $10.54M
Short-Term Investments
Other Short-Term Assets $720.0K $940.0K $300.0K
YoY Change -72.41% 213.33% 15.38%
Inventory $855.0K
Prepaid Expenses
Receivables $110.0K
Other Receivables $0.00
Total Short-Term Assets $13.31M $15.81M $11.80M
YoY Change 29.01% 33.97% 55.61%
LONG-TERM ASSETS
Property, Plant & Equipment $13.00K $17.00K $93.00K
YoY Change -75.47% -81.72% -23.14%
Goodwill $718.0K
YoY Change 0.0%
Intangibles $19.44M $19.93M
YoY Change
Long-Term Investments
YoY Change
Other Assets $126.0K $126.0K $126.0K
YoY Change 0.0% 0.0% 65.79%
Total Long-Term Assets $20.03M $20.52M $22.07M
YoY Change -0.15% -6.99% 1121.08%
TOTAL ASSETS
Total Short-Term Assets $13.31M $15.81M $11.80M
Total Long-Term Assets $20.03M $20.52M $22.07M
Total Assets $33.34M $36.33M $33.87M
YoY Change 9.75% 7.28% 260.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $981.0K $1.133M $935.0K
YoY Change -4.66% 21.18% -25.91%
Accrued Expenses $860.0K $720.0K $1.240M
YoY Change -2.27% -41.94% -6.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.945M $1.942M $2.172M
YoY Change -8.34% -10.59% -15.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $13.00K $13.00K $1.201M
YoY Change -98.85% -98.92% 500.5%
Total Long-Term Liabilities $13.00K $13.00K $1.201M
YoY Change -98.85% -98.92% 500.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.945M $1.942M $2.172M
Total Long-Term Liabilities $13.00K $13.00K $1.201M
Total Liabilities $16.70M $13.08M $3.721M
YoY Change 352.07% 251.49% 33.9%
SHAREHOLDERS EQUITY
Retained Earnings -$124.6M -$117.5M -$101.2M
YoY Change 18.44% 16.11% 13.15%
Common Stock $141.2M $140.8M $131.3M
YoY Change 7.09% 7.16% 37.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.65M $23.25M $30.14M
YoY Change
Total Liabilities & Shareholders Equity $33.34M $36.33M $33.87M
YoY Change 9.75% 7.28% 260.65%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$7.058M -$3.804M -$2.887M
YoY Change 77.83% 31.76% -9.47%
Depreciation, Depletion And Amortization $490.0K $490.0K $150.0K
YoY Change 16.67% 226.67% 650.0%
Cash From Operating Activities -$2.750M -$2.520M -$2.183M
YoY Change -8.33% 15.44% -45.21%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $4.000K
YoY Change -78.95%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 -$4.000K
YoY Change -100.0% -78.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 540.0K 288.0K 10.00M
YoY Change -97.12% 100.0%
NET CHANGE
Cash From Operating Activities -2.750M -2.520M -2.183M
Cash From Investing Activities 0.000 0.000 -4.000K
Cash From Financing Activities 540.0K 288.0K 10.00M
Net Change In Cash -2.210M -2.232M 7.813M
YoY Change -26.33% -128.57% 683.65%
FREE CASH FLOW
Cash From Operating Activities -$2.750M -$2.520M -$2.183M
Capital Expenditures $0.00 $4.000K
Free Cash Flow -$2.750M -$2.187M
YoY Change -8.33% -45.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
22000
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19768375 shares
CY2017Q1 us-gaap Share Price
SharePrice
3.85
CY2017Q1 slno Contingent Liability Payment On Achievement Of Sales Milestone
ContingentLiabilityPaymentOnAchievementOfSalesMilestone
2590000
CY2015Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8171 sqft
CY2015Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
23300
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10574000
CY2018Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
721000
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
131000
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
423000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
15808000
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
140733000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1133000
CY2018Q1 us-gaap Assets
Assets
36331000
CY2018Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
484000
CY2018Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5510000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14866000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14901000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19768375 shares
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19768375 shares
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
20000
CY2018Q1 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
453000
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1600000
CY2018Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19927000
CY2018Q1 us-gaap Liabilities
Liabilities
13312000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36331000
CY2018Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
88000
CY2018Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
625000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1942000
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126000
CY2018Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17000
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
35000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117734000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
23019000
CY2018Q1 slno Working Capital
WorkingCapital
14000000
CY2018Q1 slno Contingent Liability Payment On Achievement Of Sales Milestone
ContingentLiabilityPaymentOnAchievementOfSalesMilestone
5510000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2761000
CY2017Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
973000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
17994000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
140495000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
633000
CY2017Q4 us-gaap Assets
Assets
39022000
CY2017Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
516000
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5082000
CY2017Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.40
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17100000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17135000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19238972 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19238972 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2017Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
466000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20413000
CY2017Q4 us-gaap Liabilities
Liabilities
12487000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39022000
CY2017Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
127000
CY2017Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
225000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1733000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
343000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
35000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113979000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
26535000
CY2016Q1 slno Additional Operating Lease Office Space
AdditionalOperatingLeaseOfficeSpace
5265 sqft
CY2015Q3 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P4Y
CY2015Q3 slno Lessee Leasing Arrangements Operating Leases Increasesto Monthly Payments Term
LesseeLeasingArrangementsOperatingLeasesIncreasestoMonthlyPaymentsTerm
P3Y
CY2015Q1 slno Lessee Leasing Arrangements Operating Leases Increasesto Monthly Payments Term
LesseeLeasingArrangementsOperatingLeasesIncreasestoMonthlyPaymentsTerm
P2Y
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
185000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4332558 shares
CY2017Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
5000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7813000
CY2017Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-834000
CY2017Q1 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-4000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
119000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2017Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
-0.17
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
69000
CY2017Q1 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-2000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1019000
CY2017Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-842000
CY2017Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-16000
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
360000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.61 pure
CY2017Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2045000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-204000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-49000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1349000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10000000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
1373000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10000000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2183000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2887000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1373000
CY2017Q1 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
601000
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
135000
CY2017Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
45000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-672000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10000000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
327000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
140000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
27000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.022 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.90
CY2017Q1 us-gaap Stock Issued1
StockIssued1
17246000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5090581 shares
CY2017Q1 slno Noncash Or Part Noncash Acquisition Contingent Consideration
NoncashOrPartNoncashAcquisitionContingentConsideration
2590000
CY2017Q1 slno Noncash Expense On Shares Issued
NoncashExpenseOnSharesIssued
602000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9599742 shares
CY2018Q1 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
4220000
CY2018Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
428000
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-212000
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
SOLENO THERAPEUTICS INC
CY2018Q1 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
5310000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2232000
CY2018Q1 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
400000
CY2018Q1 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-487000
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
492000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2018Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare
-0.02
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001484565
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q1 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
3000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1867000
CY2018Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-514000
CY2018Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.17
CY2018Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3241000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
409000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-252000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
80000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2033000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
288000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
3475000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-112000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2520000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3755000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3475000
CY2018Q1 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
-19000
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
85000
CY2018Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
82000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
234000
CY2018Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
112000
CY2018Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1090000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1180000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
341000
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027 pure
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.03
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70 pure
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q1 dei Trading Symbol
TradingSymbol
SLNO
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19530311 shares
CY2018Q1 slno Classof Warrant Or Right Liquidated Damages Amount Percentof Volume Weighted Average Price
ClassofWarrantOrRightLiquidatedDamagesAmountPercentofVolumeWeightedAveragePrice
0.01 pure
CY2018Q1 slno Costs Of Issuing Common Stock And Common Stock Warrants Recorded In Accounts Payable
CostsOfIssuingCommonStockAndCommonStockWarrantsRecordedInAccountsPayable
91000
CY2018Q1 slno First Commercial Sales Milestone
FirstCommercialSalesMilestone
100000000
CY2018Q1 slno Second Commercial Sales Milestone
SecondCommercialSalesMilestone
200000000
CY2018Q1 slno Cash And Cash Equivalents Period Increase Decrease Included In Current Assets Held For Sale
CashAndCashEquivalentsPeriodIncreaseDecreaseIncludedInCurrentAssetsHeldForSale
-2000

Files In Submission

Name View Source Status
0001193125-18-164124-index-headers.html Edgar Link pending
0001193125-18-164124-index.html Edgar Link pending
0001193125-18-164124.txt Edgar Link pending
0001193125-18-164124-xbrl.zip Edgar Link pending
d571743d10q.htm Edgar Link pending
d571743dex311.htm Edgar Link pending
d571743dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slno-20180331.xml Edgar Link completed
slno-20180331.xsd Edgar Link pending
slno-20180331_cal.xml Edgar Link unprocessable
slno-20180331_def.xml Edgar Link unprocessable
slno-20180331_lab.xml Edgar Link unprocessable
slno-20180331_pre.xml Edgar Link unprocessable